Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-032-03176-1_18PMID 41225107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccine a promising immunotherapy option for head and neck cancer patients

  2024cited by this paper
• Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis

  2024cited by this paper
• A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

  2024cited by this paper
• Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity

  2024cited by this paper
• Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma

  2024cited by this paper
• Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.

  2023cited by this paper
• Oncolytic Virotherapy.

  2023cited by this paper
• Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

  2023cited by this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cited by this paper
• Targeting oral tumor microenvironment for effective therapy

  2023cited by this paper
• Personalizing Oncolytic Virotherapy

  2023cited by this paper
• Prostaglandin E₂ impacts multiple stages of the natural killer cell antitumor immune response

  2023cited by this paper
• A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers

  2022cited by this paper
• Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment

  2022cited by this paper
• Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

  2022cited by this paper
• [Oncolytic virotherapy in head and neck cancer].

  2022cited by this paper
• Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial

  2022cited by this paper
• The prognostic impact of the immune signature in head and neck squamous cell carcinoma

  2022cited by this paper
• B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

  2021cited by this paper
• Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma

  2021cited by this paper
• Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review).

  2021cited by this paper
• TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.

  2021cited by this paper
• Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

  2021cited by this paper
• Tumor-Infiltrating CD20+ B Lymphocytes: Significance and Prognostic Implications in Oral Cancer Microenvironment

  2021cited by this paper
• The Role of B Cells in Head and Neck Cancer

  2021cited by this paper
• Immunotherapeutic Strategies for Head and Neck Cancer.

  2021cited by this paper
• Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy

  2021cited by this paper
• Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

  2021cited by this paper
• Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma

  2021cited by this paper
• Genetic engineering of T cells for immunotherapy

  2021cited by this paper
• Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing

  2021cited by this paper
• Immunotherapy: The future of cancer treatment

  2021cited by this paper
• Applications of single-cell and bulk RNA sequencing in onco-immunology.

  2021cited by this paper
• Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer

  2021cited by this paper
• Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment

  2021cited by this paper
• Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC

  2020cited by this paper
• B cells are associated with survival and immunotherapy response in sarcoma

  2020cited by this paper
• Introduction to Oncolytic Virotherapy.

  2020cited by this paper
• The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites

  2020cited by this paper
• Oncolytic virotherapy: Challenges and solutions.

  2020cited by this paper
• Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer

  2020cited by this paper
• PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis.

  2020cited by this paper
• Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma

  2020cited by this paper
• Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma

  2020cited by this paper
• M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF

  2020cited by this paper
• Tumor immune microenvironment in head and neck cancers

  2020cited by this paper
• Biomarkers for immunotherapy response in head and neck cancer.

  2020cited by this paper
• Regulatory T Cells in the Tumor Microenvironment.

  2020cited by this paper
• Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

  2020cited by this paper
• Neutrophil‐to‐lymphocyte ratio as a prognostic indicator for overall and cancer‐specific survival in squamous cell carcinoma of the head and neck

  2020cited by this paper
• Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer

  2020cited by this paper
• Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.

  2019cited by this paper
• Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

  2019cited by this paper
• Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.

  2019cited by this paper
• CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer

  2019cited by this paper
• Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer.

  2019cited by this paper
• Evaluation of Cd8+ and natural killer cells defense in oral and oropharyngeal squamous cell carcinoma.

  2019cited by this paper
• Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer

  2019cited by this paper
• 17th International Congress of Immunology, 19–23 October 2019, Beijing, China

  2019cited by this paper
• Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

  2019cited by this paper
• Tertiary lymphoid structures in the era of cancer immunotherapy

  2019cited by this paper
• STAT1 inhibits T‐cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma

  2019cited by this paper
• Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

  2019cited by this paper
• Immunotherapy for head and neck cancer: Recent advances and future directions.

  2019cited by this paper
• The Janus Face of Tumor Microenvironment Targeted by Immunotherapy

  2019cited by this paper
• Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

  2019cited by this paper
• Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

  2019cited by this paper
• Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy

  2019cited by this paper
• Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects

  2019cited by this paper
• Immunotherapy in Oral Cancer

  2019cited by this paper
• Dendritic cells in cancer immunology and immunotherapy

  2019cited by this paper
• Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

  2019cited by this paper
• Immunotherapy for Head and Neck Cancer.

  2019cited by this paper
• NK Cell Metabolism and Tumor Microenvironment

  2019cited by this paper
• Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

  2019cited by this paper
• Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

  2019cited by this paper
• Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment

  2019cited by this paper
• CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α

  2019cited by this paper
• Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma

  2019cited by this paper
• Tumour-associated neutrophils in patients with cancer

  2019cited by this paper
• Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

  2019cited by this paper
• Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma

  2019cited by this paper
• Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

  2019cited by this paper
• Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

  2019cited by this paper
• Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review

  2019cited by this paper
• Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma

  2019cited by this paper
• Targeting the IL-6/JAK/STAT3 signalling axis in cancer

  2018cited by this paper
• Immune Checkpoint Inhibition in Head and Neck Cancer

  2018cited by this paper
• CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

  2018cited by this paper
• Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer

  2018cited by this paper
• Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets

  2018cited by this paper
• γ‐Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma

  2018cited by this paper
• Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells

  2018cited by this paper
• New Therapies in Head and Neck Cancer.

  2018cited by this paper
• Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway

  2018cited by this paper
• Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients

  2018cited by this paper
• Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis

  2018cited by this paper
• Turning foes to friends: targeting cancer-associated fibroblasts

  2018cited by this paper
• Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer

  2018cited by this paper
• Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

  2018cited by this paper

• No citing papers are available for this paper.